Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry.

British journal of haematology (2014-07-06)
Caterina Borgna-Pignatti, Maria Chiara Garani, Gian Luca Forni, Maria Domenica Cappellini, Elena Cassinerio, Carmelo Fidone, Vincenzo Spadola, Aurelio Maggio, Gaetano Restivo Pantalone, Antonio Piga, Filomena Longo, Maria Rita Gamberini, Paolo Ricchi, Silvia Costantini, Domenico D'Ascola, Paolo Cianciulli, Maria Eliana Lai, Maria Paola Carta, Angela Ciancio, Paola Cavalli, Maria Caterina Putti, Susanna Barella, Giovanni Amendola, Saveria Campisi, Marcello Capra, Vincenzo Caruso, Grazia Colletta, Stefano Volpato
RESUMO

The risk of developing hepatocellular carcinoma (HCC) in patients with thalassaemia is increased by transfusion-transmitted infections and haemosiderosis. All Italian Thalassaemia Centres use an ad hoc form to report all diagnoses of HCC to the Italian Registry. Since our last report, in 2002, up to December 2012, 62 new cases were identified, 52% of whom were affected by thalassaemia major (TM) and 45% by thalassaemia intermedia (TI). Two had sickle-thalassaemia (ST). The incidence of the tumour is increasing, possibly because of the longer survival of patients and consequent longer exposure to the noxious effects of the hepatotropic viruses and iron. Three patients were hepatitis B surface antigen-positive, 36 patients showed evidence of past infection with hepatitis B virus (HBV). Fifty-four patients had antibodies against hepatitis C virus (HCV), 43 of whom were HCV RNA positive. Only 4 had no evidence of exposure either to HCV or HBV. The mean liver iron concentration was 8 mg/g dry weight. Therapy included chemoembolization, thermoablation with radiofrequency and surgical excision. Three patients underwent liver transplant, 21 received palliative therapy. As of December 2012, 41 patients had died. The average survival time from HCC detection to death was 11·5 months (1·4-107·2 months). Ultrasonography is recommended every 6 months to enable early diagnosis of HCC, which is crucial to decrease mortality.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
Iron, ≥99%, reduced, powder (fine)
Sigma-Aldrich
Carbonyl iron, ≥97% Fe basis
Sigma-Aldrich
Ferritin from equine spleen, Type I, saline solution
Sigma-Aldrich
Iron, powder, −325 mesh, 97%
Sigma-Aldrich
Iron, chips, 99.98% trace metals basis
Sigma-Aldrich
Iron, nanopowder, 35-45 nm particle size, 99.5% trace metals basis
Sigma-Aldrich
Iron, puriss. p.a., carbonyl-Iron powder, low in magnesium and manganese compounds, ≥99.5% (RT)
Sigma-Aldrich
Iron, granular, 10-40 mesh, >99.99% trace metals basis
Sigma-Aldrich
Iron, foil, thickness 0.1 mm, ≥99.9% trace metals basis
Sigma-Aldrich
Iron, foil, thickness 0.25 mm, ≥99.99% trace metals basis
Sigma-Aldrich
Iron, wire, diam. 1.0 mm, ≥99.9% trace metals basis
Sigma-Aldrich
Iron, carbon coated magnetic, nanopowder, 25 nm avg. part. size, 99.5% trace metals basis
Sigma-Aldrich
Ferritin from human spleen, Type V, 10 μg/mL in 0.15 M NaCl, 10 mM Tris, pH 8.0, containing 0.1% sodium azide
Iron, IRMM®, certified reference material, 0.5 mm wire
Iron, foil, 300x300mm, thickness 0.1mm, hard, 99.5%
Sigma-Aldrich
Iron, rod, diam. 6.3 mm, 99.98% trace metals basis
Iron, foil, 25x25mm, thickness 1.0mm, as rolled, 99.5%
Iron, foil, 100x100mm, thickness 1.0mm, as rolled, 99.99+%
Iron, foil, 25x25mm, thickness 2mm, as rolled, 99.99+%
Iron, foil, 100x100mm, thickness 0.5mm, hard, 99.5%
Iron, foil, 150x150mm, thickness 3.0mm, as rolled, 99.5%
Iron, rod, 100mm, diameter 2.0mm, as drawn, 99.95%
Iron, rod, 200mm, diameter 2.0mm, as drawn, 99.99+%
Iron, rod, 500mm, diameter 9.5mm, as drawn, soft ingot 99.8+%
Iron, foil, 10mm disks, thickness 0.01mm, 99.85%
Iron, foil, 10mm disks, thickness 0.01mm, 99.99+%
Iron, foil, 10mm disks, thickness 0.020mm, 99.85%
Iron, foil, 10mm disks, thickness 0.025mm, as rolled, 99.99+%
Iron, foil, 10mm disks, thickness 0.025mm, hard, 99.5%
Iron, foil, 10mm disks, thickness 0.038mm, hard, 99.5%